Syros Pharmaceuticals (SYRS) Competitors $0.28 -0.01 (-4.03%) (As of 11:27 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SYRS vs. HCWB, BIVI, RNXT, KALA, BLRX, DARE, LSB, PLUR, INKT, and MRKRShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include HCW Biologics (HCWB), BioVie (BIVI), RenovoRx (RNXT), KALA BIO (KALA), BioLineRx (BLRX), Daré Bioscience (DARE), Lakeshore Biopharma (LSB), Pluri (PLUR), MiNK Therapeutics (INKT), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. HCW Biologics BioVie RenovoRx KALA BIO BioLineRx Daré Bioscience Lakeshore Biopharma Pluri MiNK Therapeutics Marker Therapeutics HCW Biologics (NASDAQ:HCWB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation. Does the media refer more to HCWB or SYRS? In the previous week, Syros Pharmaceuticals had 11 more articles in the media than HCW Biologics. MarketBeat recorded 20 mentions for Syros Pharmaceuticals and 9 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.34 beat Syros Pharmaceuticals' score of -0.04 indicating that HCW Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syros Pharmaceuticals 0 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is HCWB or SYRS more profitable? Syros Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -1,067.82%. HCW Biologics' return on equity of -2,516.84% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets HCW Biologics-1,067.82% -2,516.84% -132.95% Syros Pharmaceuticals N/A -3,369.56%-97.04% Which has better valuation & earnings, HCWB or SYRS? HCW Biologics has higher earnings, but lower revenue than Syros Pharmaceuticals. HCW Biologics is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHCW Biologics$2.84M10.51-$24.99M-$1.00-0.79Syros Pharmaceuticals$9.94M0.75-$164.57M-$3.03-0.09 Does the MarketBeat Community believe in HCWB or SYRS? Syros Pharmaceuticals received 361 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 63.49% of users gave Syros Pharmaceuticals an outperform vote. CompanyUnderperformOutperformHCW BiologicsOutperform Votes6100.00% Underperform VotesNo VotesSyros PharmaceuticalsOutperform Votes36763.49% Underperform Votes21136.51% Do analysts recommend HCWB or SYRS? Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 1,097.75%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syros Pharmaceuticals is more favorable than HCW Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more volatility & risk, HCWB or SYRS? HCW Biologics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Do insiders and institutionals hold more shares of HCWB or SYRS? 3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 49.9% of HCW Biologics shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySyros Pharmaceuticals beats HCW Biologics on 11 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.47M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.094.9791.2813.60Price / Sales0.75371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book-0.6810.306.906.33Net Income-$164.57M$153.61M$118.83M$225.93M7 Day Performance1.16%-1.73%-1.92%-0.96%1 Month Performance-87.58%-7.26%-3.75%1.06%1 Year Performance-90.40%31.10%31.37%26.59% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.0927 of 5 stars$0.28-4.0%$3.33+1,097.7%-89.9%$7.47M$9.94M-0.09120Analyst RevisionHCWBHCW Biologics1.1093 of 5 stars$0.79-16.7%N/A-12.3%$29.84M$2.84M0.0040Gap DownBIVIBioVie0.625 of 5 stars$3.15-6.3%$4.00+27.0%-24.0%$29.39MN/A0.0010RNXTRenovoRx2.6223 of 5 stars$1.20+0.8%$6.13+410.4%+98.7%$28.80MN/A-2.126News CoveragePositive NewsKALAKALA BIO4.0824 of 5 stars$6.20-3.6%$15.00+141.9%+7.8%$28.58M$3.89M0.0030BLRXBioLineRx1.9751 of 5 stars$0.35-35.4%$21.00+5,862.5%-67.9%$28.16M$4.80M0.0040News CoverageGap DownHigh Trading VolumeDAREDaré Bioscience2.203 of 5 stars$3.18flat$24.00+654.7%-23.9%$27.67M$2.81M-5.3830LSBLakeshore Biopharma0.2075 of 5 stars$2.94+12.2%N/AN/A$27.37M$80.82M0.00773Gap DownPLURPluri0.1524 of 5 stars$4.92-2.8%N/A+11.5%$27.36M$330,000.00-0.82150INKTMiNK Therapeutics3.2235 of 5 stars$0.69-2.1%$6.50+842.0%-34.1%$27.29MN/A-1.8130Analyst RevisionGap DownMRKRMarker Therapeutics3.8639 of 5 stars$3.05-4.1%$19.00+523.0%+17.8%$27.21M$3.31M0.0060Gap Down Related Companies and Tools Related Companies HCWB Alternatives BIVI Alternatives RNXT Alternatives KALA Alternatives BLRX Alternatives DARE Alternatives LSB Alternatives PLUR Alternatives INKT Alternatives MRKR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYRS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
